Background-Circulating biomarkers can offer insight into subclinical cardiovascular stress and thus have the potential to aid in risk stratification and tailoring of therapy. Methods and Results-We measured plasma levels of 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patients with stable coronary artery disease and preserved left ventricular ejection fraction who were randomized to trandolapril or placebo as part of the Prevention of Events With Angiotensin Converting Enzyme (PEACE) trial. After adjustment for clinical cardiovascular risk predictors and left ventricular ejection fraction, elevated levels of MR-proANP, MR-proADM, and CT-proET-1 were independently associated with the risk of cardiovascular death or heart failure (hazard ratios per 1-SD increase in log-transformed biomarker levels of 1.97, 1.48, and 1.47, respectively; PՅ0.002 for each biomarker). These 3 biomarkers also significantly improved metrics of discrimination when added to a clinical model. Trandolapril significantly reduced the risk of cardiovascular death or heart failure in patients who had elevated levels of Ն2 biomarkers (hazard ratio, 0.53; 95% confidence interval, 0.36 -0.80), whereas there was no benefit in patients with elevated levels of 0 or 1 biomarker (hazard ratio, 1.09; 95% confidence interval, 0.74 -1.59; P interaction ϭ0.012). Conclusions-In patients with stable coronary artery disease and preserved left ventricular ejection fraction, our results suggest that elevated levels of novel biomarkers of cardiovascular stress may help identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy. (Circulation. 2012;125:233-240.)
arginine vasopressin, a vasoconstrictor that is secreted from the posterior pituitary in response not only to osmotic stimuli but also to hemodynamic changes detected by cardiac and vascular baroreceptors. 12 Higher levels of these biomarkers have been associated with an increased risk of death and/or heart failure events in patients with established heart failure. [13] [14] [15] [16] The availability of an assay panel for these 4 biomarkers of cardiovascular stress that have shown promise in patients with established heart failure created the opportunity to investigate their utility in a broader population.
Angiotensin-converting enzyme (ACE) inhibitors substantially reduce the risk of death and heart failure events in patients with heart failure, with the greatest benefit in those patients with the most clinically severe heart failure. 17 Among patients with acute myocardial infarction (MI), the benefit of ACE inhibitors is greatest in those with high-risk clinical features such as anterior MI or depressed left ventricular systolic function. 18 In contrast, the role of ACE inhibitors in lower-risk patients with stable coronary artery disease (CAD) without heart failure is less clear. 19 -21 We explored the hypotheses that in such patients, elevated levels of midregional (MR) pro-ANP, MR-proADM, C-terminal proET-1 (CT-proET-1), and copeptin would offer prognostic value for cardiovascular death and heart failure independently of clinical risk factors and would identify patients who derive greater clinical benefit from the use of an ACE inhibitor. We tested these hypotheses by measuring plasma levels of these novel biomarkers of cardiovascular stress in 3717 patients with stable CAD and preserved left ventricular ejection fraction (LVEF) who were randomized to trandolapril or placebo as part of the Prevention of Events With Angiotensin Converting Enzyme (PEACE) trial.
Methods

Patient Population
This study involved 3717 patients with documented stable CAD who had been enrolled in the PEACE trial (www.ClinicalTrials.gov; unique identifier, NCT00000558) and provided a sample of blood at the time of enrollment. The design and main outcomes of the PEACE trial have been published previously, 21 and salient features are detailed in the Methods section and Table I in the online-only Data Supplement. In brief, subjects were free of heart failure at baseline, and none had been hospitalized with an acute coronary syndrome or had undergone coronary revascularization within the 3 months preceding trial entry. Both the parent clinical trial and this substudy were approved by the relevant institutional review boards, and informed consent was obtained from all patients.
Biomarker Analyses
Baseline plasma levels of MR-proANP, 22 MR-proADM, 23 CTproET-1, 24 and copeptin 25 (assays from B.R.A.H.M.S. GmbH, Henningsdorf, Germany) were determined in the Thrombolysis in Myocardial Infarction (TIMI) Clinical Trials Laboratory (Boston, MA) as detailed in the Methods section and Table II in the online-only Data Supplement. Baseline levels of NT-proBNP and cardiac troponin T (cTnT) measured with a highly sensitive assay had been determined in this population, as previously published and summarized in the Methods section in the online-only Data Supplement. 6, 26 All testing was performed by personnel blinded to clinical outcomes and treatment allocation.
Outcomes
On the basis of prior data regarding the predictive ability of biomarkers of cardiac stress, 6 the primary outcome in this analysis was the composite of cardiovascular death or hospitalization for heart failure. Additionally, we explored other major adverse cardiovascular events that had been recorded in patients in the trial, including all-cause death, acute MI, acute stroke, and coronary revascularization (percutaneous or surgical). Event adjudication is detailed in the Methods section in the online-only Data Supplement. All clinical events were classified before biomarkers were measured.
Statistical Analyses
Baseline characteristics are reported as meanϮSD for normally distributed continuous variables and as counts and percentages for categorical variables. Wilcoxon rank-sum and 2 tests for trend were used to test for differences in continuous and categorical baseline characteristics between quartiles of biomarkers. The Spearman correlation was used to calculate the association between different biomarkers and categorized based on standard cut points. 27 The cumulative incidences of clinical outcomes across quartiles of each biomarker were compared by use of a log-rank test. Cox proportional-hazards models were used to examine the association between biomarker levels and outcome data. In these models, biomarker levels were examined both as a continuous variable (after natural logarithmic transformation) and as a categorical variable by quartiles. Associations were adjusted for age, sex, weight, history of hypertension, history of diabetes mellitus, current tobacco use, prior MI, prior percutaneous coronary intervention or coronary artery bypass grafting, systolic blood pressure, estimated glomerular filtration rate, ratio of apolipoprotein B to apolipoprotein A, LVEF, aspirin use, ␤-blocker use, and lipid-lowering medication use. Starting with a model containing the aforementioned clinical covariates, a forward selection algorithm (PϽ0.05 to enter the model) was used to select among the 4 novel biomarkers, as well as NT-proBNP and cTnT. The incremental performance of the biomarkers in addition to clinical predictors was further evaluated by calculating changes in the C statistic, integrated discrimination improvement, and category-free net reclassification improvement metrics (see the Methods section in the online-only Data Supplement for further details). 28 -30 To examine for heterogeneity in the effect of trandolapril on the risk of cardiovascular death or heart failure, hazard ratios (HRs) were calculated in patients who were and were not in the highest-risk category as defined by being in the top quartile of a biomarker level. To test for statistically significant effect modification, a Cox proportional hazards model was created that included a term for trandolapril, a term for biomarker risk category, and an interaction term.
A value of PϽ0.05 was considered to indicate statistical significance, and all tests were 2 sided. No adjustment for multiple comparisons was performed. Although based on previous work with these biomarkers in other populations, all of the analyses we have performed in this biomarker substudy are inherently exploratory. Analyses were performed with STATA/IC (version 10.1, STATA Corp, College Station, TX) and R (version 2.12.1).
Results
Baseline Characteristics of the Patients and Biomarker Levels
Baseline measurements of the 4 novel biomarkers were available for 3717 patients from the PEACE trial. The clinical characteristics of the patients are given in Table 1 . By design, all patients had stable CAD, and LVEF was preserved at a meanϮSD value of 58.7Ϯ9.6%. Median levels of MR-proANP, MR-proADM, CT-proET-1, and copeptin at baseline in patients in the PEACE trial were 90.45 pmol/L (25th-75th percentile, 63.68 -128.3 pmol/L), 0.53 nmol/L (25th-75th percentile, 0.45-0.64 nmol/L), 47.82 pmol/L (25th-75th percentile, 39.04 -57.02 pmol/L), and 6.47 pmol/L (25th-75th percentile, 0 -10.67 pmol/L), respectively. The levels tended to be higher than those seen in healthy populations, but with the exception of MR-proADM, the majority of values were lower than the 97.5th percentile reported in healthy populations and lower than the values in patients with overt heart failure (Table II in the online-only Data Supplement). Characteristics of patients according to quartiles of biomarker levels are shown in Tables III through VI in the online-only Data Supplement. In general, higher levels of biomarkers of cardiovascular stress were positively associated with greater age and prevalence of hypertension and lower estimated glomerular filtration rate. LVEF was inversely associated with MR-proANP and copeptin levels but differed by only 2.0 and 1.0 absolute percentage points between the top and bottom quartiles for the 2 biomarkers, respectively. Among the novel biomarkers, the only moderately strong correlation was between MR-proADM and CT-proET-1 (rϭ0.63); the others were moderate to low (rՅ0.44; Table VII in the online-only Data Supplement). As expected, there was a strong positive correlation between levels of MR-proANP and NT-proBNP (rϭ0.76), but correlations of NT-proBNP and cTnT with other markers were weak (rՅ0.38; Table VII in the online-only Data Supplement).
Clinical Outcomes
Among patients allocated to the placebo arm of the PEACE trial, higher baseline levels of each of the 4 novel biomarker of cardiovascular stress were strongly associated with the subsequent risk of cardiovascular death or heart failure (the composite of which occurred in 114 patients), with up to approximately a doubling of the risk per each 1-SD increase in log-transformed biomarker levels (PՅ0.002 for each biomarker; Table 2 ). Risk increased across quartiles, especially the fourth quartile ( Figure  1 ). Similar associations were seen between biomarker levels and the risk of cardiovascular death (which occurred in 67 patients) and of heart failure individually (which occurred in 56 patients; Table VIII in the online-only Data Supplement).
After adjustment for traditional clinical risk predictors, estimated glomerular filtration rate, and LVEF (see Methods for a detailed list of covariates), elevated levels of MR-proANP, MR-proADM, and CT-proET-1 remained significantly associated with an increased risk of cardiovascular death or heart failure, ranging from 47% higher risk to a near doubling of the risk per each 1-SD increase in log-transformed biomarker levels (PՅ0.002 for each biomarker); in terms of quartile analysis, the risk was most pronounced for those patients in the top quartile, who had almost 3 times to Ͼ5 times the risk seen for patients in the lowest quartile. In contrast, after multivariable adjustment, the association with copeptin was no longer significant ( Table  3) . As was the case for the unadjusted analyses, similar associations were seen between biomarker levels and the risk of cardiovascular death and of heart failure individually (Table VIII in the online-only Data Supplement). Compared with cardiovascular death, the associations with the less cardiovascular-specific end point of all-cause death were significant but weaker (Table IX in the online-only Data Supplement). As expected on the basis of prior work, 6, 26 there were nonsignificant adjusted associations between levels of novel biomarkers of cardiovascular stress and the risk of acute MI, stroke, or coronary revascularization, with the exception of MR-proANP and stroke (Pϭ0.043; Table IX in the onlineonly Data Supplement). CV indicates cardiovascular; HR, hazard ratio; CI, confidence interval; MR-proANP, midregional pro-atrial natriuretic peptide; MR-proADM, midregional pro-adrenomedullin; and CT-proET-1, C-terminal pro-endothelin-1. A total of 114 of the 1868 patients allocated to placebo experienced CV death or heart failure. Each biomarker was analyzed separately. In quartile analyses, "multiple partial" refers to a 3-df test for the addition of all quartiles and "trend" refers to a 1-df test for linear trend across quartiles.
We have previously measured NT-proBNP and cTnT in this population, and the association of those biomarkers with cardiovascular death or heart failure in a model adjusted for the aforementioned clinical covariates is shown in Table X in the online-only Data Supplement. Ranking each biomarker individually on the basis of the magnitude of risk (HR) per 1 SD gives the following order: MR-proANP (1.97), NT-proBNP (1.73), MR-proADM (1.48), CT-proET-1 (1.47), and cTnT (1.37). Given the correlation between the biomarkers and that none is established for routine use in this population, we used an unbiased forward selection algorithm to create a multimarker model. The only 2 biomarkers to enter and remain in a model already containing clinical covariates were MR-proANP (adjusted HR, 1.79; 95% confidence interval [CI], 1.41-2.26; PϽ0.001) and MR-proADM (adjusted HR, 1.27; 95% CI, 1.07-1.51; Pϭ0.007).
The addition of MR-proANP, MR-proADM, and CTproET-1 individually to the clinical model significantly improved metrics of discrimination (Table 4 ). In contrast, the addition of copeptin did not improve these metrics. The addition Figure 1 . Cumulative incidence curves for the composite of cardiovascular death or heart failure among patients in the placebo arm of the Prevention of Events With Angiotensin Converting Enzyme (PEACE) trial (nϭ1868) categorized by quartiles of midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), or copeptin. P values are for log-rank test for trend across quartiles. CV indicates cardiovascular; HR, hazard ratio; CI, confidence interval; MR-proANP, midregional pro-atrial natriuretic peptide; MR-proADM, midregional pro-adrenomedullin; and CT-proET-1, C-terminal pro-endothelin-1. Covariates in the model include standard clinical factors: age, sex, weight, history of hypertension, history of diabetes mellitus, current tobacco use, prior myocardial infarction, prior percutaneous coronary intervention or coronary artery bypass graft surgery, systolic blood pressure, estimated glomerular filtration rate, ratio of apolipoprotein B to A, left ventricular ejection fraction, aspirin use, ␤-blocker use, and lipid-lowering medication use. Each biomarker was analyzed separately in the placebo arm. In quartile analyses, "multiple partial" refers to a 3-df test for the addition of all quartiles and "trend" refers to a 1-df test for linear trend across quartiles.
of all 3 biomarkers to the clinical model improved the C statistic from 0.768 to 0.809 and yielded an integrated discrimination improvement of 4.6% and an net reclassification improvement of 0.435 (all PՅ0.0005). Adding MR-proANP, MR-proADM, and CT-proET-1 uniformly and significantly improved the C statistic of multivariable models already containing clinical covariates, regardless of whether NT-proBNP, cTnT, or both were also in the model; conversely, adding NT-proBNP and cTnT to a model containing clinical covariates as well as MR-proANP, MR-proADM, and CT-proET-1 did not improve the C statistic (Table XI in 
Interaction With Trandolapril Therapy
In the overall biomarker cohort, treatment with trandolapril resulted in an HR of 0.80 (95% CI, 0.61-1.05) for cardiovascular death or heart failure. Notably, however, among patients having an MR-proANP, MR-proADM, or CT-proET-1 level in the top quartile and thus at the highest risk of cardiovascular death or heart failure based on these biomarkers, trandolapril significantly reduced the risk of cardiovascular death or heart failure by 34% to 44%, whereas no benefit was observed among those with lower levels (Figure 2A ). In contrast, there was no significant benefit from treatment with trandolapril among patients in the highest quartiles of either NT-proBNP or cTnT ( Figure I in the online-only Data Supplement).
A gradient of benefit (P interaction ϭ0.016) with trandolapril therapy was observed in patients categorized according to whether they had elevated levels of 0 (nϭ2037), 1 (nϭ891), 2 (nϭ472), or all 3 (nϭ317) novel biomarkers that we found to be associated with cardiovascular death or heart failure in adjusted analyses ( Figure 2B ). When the results were dichotomized, among the 2928 patients (79% of the biomarker cohort) with Յ1 elevated biomarker, there was no benefit of trandolapril therapy on the risk of cardiovascular death or heart failure (HR, 1.09; The P values for interaction were 0.16, 0.02, 0.09, and 0.72 for midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and copeptin, respectively. B, Patients are categorized by the number of biomarkers (MR-proANP, MR-proADM, and CT-proET-1) in the top quartile; the P value for interaction is 0.016. In A and B, the diamonds indicate the effect in the entire biomarker cohort, with the center indicating the point estimate and the left and right ends indicating the 95% confidence interval (CI). The squares and circles indicate the point estimate, and the horizontal lines indicate the 95% CIs for the effect in each subgroup. HR indicates hazard ratio.
95% CI, 0.74 -1.59), whereas among the 789 patients (21% of the biomarker cohort) with Ն2 elevated biomarkers, trandolapril significantly reduced the rate of cardiovascular death or heart failure (HR, 0.53; 95% CI, 0.36 -0.80; Pϭ0.002, P interaction ϭ0.012; Figure 3 ). The absolute risk reduction over 6 years in this latter group was 7.5%; thus, in this subset, 14 patients would need to be treated with trandolapril for 6 years to prevent a cardiovascular death or hospitalization for heart failure.
Discussion
In an exploratory analysis among a large cohort of patients with stable CAD and preserved LVEF, we have demonstrated that elevated levels of 3 novel biomarkers of cardiovascular stress are independently associated with the subsequent risk of cardiovascular death and heart failure. Specifically, MRproANP, MR-proADM, and CT-proET-1 were associated with cardiovascular death or heart failure independently of clinical factors, renal function, and LVEF, ranging from 47% higher risk to a near doubling of the risk per each 1-SD increase in log-transformed biomarker levels and almost 3 times to Ͼ5 times the risk for patients in the highest compared with the lowest quartile. In contrast, a fourth biomarker, copeptin, was not independently associated with the risk of cardiovascular events. Moreover, and in contrast to previous results with other biomarkers, including NTproBNP and cTnT, 6, 26, 31 elevated levels of these 3 biomarkers identified patients in whom, despite appearing to be at low risk clinically, therapy with an ACE inhibitor resulted in a significant reduction in the risk of cardiovascular death or heart failure.
We used assays for the prohormones ANP, ADM, and ET-1 because the prohormones are released in an equimolar ratio to the vasoactive hormones but have a longer half-life. When possible, we also used assays for a midregional fragment because these fragments are more stable in vivo and ex vivo than the amino-or carboxy-terminal part of the prohormone, thereby minimizing the risk of underestimation of levels as a result of early degradation of crucial epitopes at the extreme ends of the molecule. 32 In studies of patients with established heart failure, elevated levels of MR-proANP, MR-proADM, and CT-proET-1 have been shown to be associated with mortality independently of clinical variables, and the biomarkers have displayed prognostic and discriminatory value that has compared favorably with BNP and/or NT-proBNP. [13] [14] [15] Concordant with those observations, in our data set, we found that during the creation of a multimarker model adjusted for clinical factors, MR-proANP and MR-proADM proved to be the strongest 2 biomarkers, superior to NT-proBNP and cTnT measured with a highly sensitive assay. Because this was a clinical rather than a mechanistic study, we can only speculate as to the reasons for the superior performance, which could be related to subtle differences in the respective pathobiology underlying elevation of each of the biomarkers or could stem from more favorable analytic properties that translate into a better reflection of subclinical cardiovascular pathology. Regardless, our data are supported by and extend previous findings regarding these biomarkers and atherosclerosis reported by Schnabel and colleagues 7 in several ways, including studying patients who were free of heart failure at baseline and whose LVEF was known and incorporated into all multivariable models, using patients enrolled from a much broader number of clinical centers, and examining the specific clinical events that biomarkers of cardiac stress are best suited to predict, namely cardiovascular death and heart failure, rather than a composite of death or MI.
Critically, whereas other biomarker analyses have been embedded in observational cohorts, we had the benefit of studying these biomarkers in a randomized clinical trial, allowing us to examine the interaction between baseline biomarker levels and the efficacy of the randomized therapy without concern for the inherent bias in examining nonrandomly allocated therapies. Using a panel of these novel biomarkers of cardiovascular stress, we were able to identify approximately one fifth of enrolled patients with stable CAD in whom ACE inhibitor therapy nearly halved the risk of cardiovascular death or heart failure. Our findings are conceptually analogous to the results of Richards and colleagues, 33, 34 who showed that elevated levels of biomarkers of cardiovascular stress identified patients with ischemic left ventricular dysfunction who benefited from ␤-blockade.
Current practice guidelines for the management of patients with stable CAD recommend ACE inhibitor therapy in those patients with an LVEF Ͻ40%; in addition, in part on the basis of data from the Heart Outcomes Prevention Evaluation (HOPE) trial, ACE inhibitors are recommended for patients who are relatively high risk and/or have another compelling clinical indication (eg, hypertension, diabetes mellitus, or chronic kidney disease). 35 In contrast, for lower-risk patients like those in the PEACE trial, in which the event rate in the placebo arm was lower than the event rate in the ACE inhibitor arm from the HOPE trial, the guidelines note that it is reasonable but not recommended to use ACE inhibitors when cardiovascular risk factors are well controlled and revascularization has been performed. Our data now support the hypothesis that within this very large population of patients who appear to be of lower risk clinically, biomarkers of cardiovascular stress levels may be useful to help guide such decision making. Although additional prospective analyses will need to be done if these biomarkers become available for routine clinical use in the United States, targeting long-term drug therapy based on a panel of biomarkers should be cost effective.
Several potential limitations of our study deserve consideration. The PEACE clinical trial population, which was predominantly a white, male population Ͼ50 years of age, is not representative of the general population. However, the clinical and laboratory characteristics of patients in this study are typical of patients with stable coronary disease, and a high proportion of patients were treated with ␤-blockers and lipid-lowering therapy. Blood samples were obtained from only a subgroup of the participants in the overall PEACE trial, but there were no clinically relevant differences between patients who did and did not participate in the biomarker substudy. Banked biosamples were used, but any sample degradation should be random with respect to cardiovascular outcomes, and thus any resultant misclassification should only bias toward the null hypothesis. The formation of the multimarker score for interaction with therapy should be considered exploratory, and the optimal combination of biomarkers and their cut points merits validation in additional populations. Heart failure events were not a component of the prespecified primary outcome in the original trial design but are a well-established outcome predicted by biomarkers of cardiac stress and prevented by ACE inhibitors in other populations. 6, 19, 20, 26 
Conclusion
In apparently low-risk patients with stable CAD and preserved LVEF, elevated levels of novel biomarkers reflecting cardiovascular stress may be useful both to identify patients who are at higher risk of cardiovascular death and heart failure and to select patients who derive a significant benefit from ACE inhibitor therapy.
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CLINICAL PERSPECTIVE
The benefit of angiotensin-converting enzyme inhibitors in low-risk patients with stable coronary artery disease without heart failure remains controversial, and current practice guidelines note that it is reasonable but not recommended to use angiotensin-converting enzyme inhibitors when cardiovascular risk factors are well controlled and revascularization has been performed. We now demonstrate that elevated levels of 3 novel biomarkers of cardiovascular stress, midregional pro-atrial natriuretic peptide, midregional pro-adrenomedullin, and C-terminal pro-endothelin-1, are associated with the subsequent risk of cardiovascular death and heart failure independently of clinical factors (adjusted hazard ratios per 1-SD increase of 1.97, 1.48, and 1.47, respectively; PՅ0.002 for each biomarker). Furthermore, elevated levels of these biomarkers identified patients in whom therapy with an angiotensin-converting enzyme inhibitor resulted in a significant reduction in the risk of cardiovascular death or heart failure. Specifically, trandolapril significantly reduced the risk of cardiovascular death or heart failure in patients who had elevated levels of Ն2 biomarkers (hazard ratio, 0.53; 95% confidence interval, 0.36 -0.80), whereas there was no benefit in patients with elevated levels of 0 or 1 biomarker (hazard ratio, 1.09; 95% confidence interval, 0.74 -1.59; P interaction ϭ0.012).
Thus, in patients with stable coronary artery disease and preserved left ventricular ejection fraction, elevated levels of novel biomarkers of cardiovascular stress identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.
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Supplemental Methods
Patient population
In the overall PEACE trial, a total of 8290 patients with documented stable coronary artery disease and preserved left ventricular ejection fraction were randomized at 187 clinical centers in the United States, Canada, and Europe to trandolapril or placebo from November 1996 through June 2000. Subjects were followed for a median of 4.8 years. As part of the study protocol, a sample of venous blood was obtained in EDTA-treated tubes at the time of enrollment. Participation in the biomarker substudy was at the discretion of each clinical center and there were no clinically relevant differences between patients included in the substudy and the overall trial population (Supplemental Table 1 GmbH, Henningsdorf, Germany). NT-proBNP levels were determined with an electrochemiluminescence immunoassay on a Modular platform (Roche Diagnostics, Bsel, Switzerland). Cardiac troponin T (cTnT) levels
were measured with a highly sensitive assay on an autoanalyzer (cobas e 411, Roche Diagnostics, Penzberg, Germany).
Outcomes
All clinical events were confirmed by a review of medical records. Cardiovascular death, MI, and stroke underwent blinded review by an outcomes committee. Heart failure was classified by centrally trained local staff and confirmed by staff at the coordinating center through a review of hospital records. For an event to be classified as heart failure, hospitalization with a primary cause of heart failure was required.
Statistical analyses
As described by Pencina and colleagues, the integrated discrimination improvement (IDI) is a method to quantify the differences in the probabilities for events and non-events based on the addition of the new biomarkers to the model and can be viewed as difference between the improvement in average sensitivity and any potential increase in average "one minus specificity". The net re-classification improvement (NRI) is the probability that patients are appropriately assigned to a higher or lower risk. We calculated NRI using Harrell's technique, as programmed in R, which evaluates the change in the estimated risk as a continuous variable and therefore is not dependent on a priori categorization. Data presented are mean SD for normally distributed continuous variables and n (%) for dichotomous variables. CABG = coronary artery bypass grafting; DBP = diastolic blood pressure; GFR = glomerular filtration rate; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI = percutaneous coronary intervention; SBP = systolic blood pressure. Data presented are mean SD for normally distributed continuous variables and n (%) for dichotomous variables. BMI = body mass index; CABG = coronary artery bypass grafting; DBP = diastolic blood pressure; GFR = glomerular filtration rate; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI = percutaneous coronary intervention; SBP = systolic blood pressure. 
MR-proANP
n/a n/a n/a n/a n/a n/a 1.59 (1.14-2. 22) 0.007 n/a n/a 1.50 (1.06-2.12) 0.021
MR-proADM
n/a n/a n/a n/a n/a n/a n/a n/a 1.25 (1.04-1.50) 0.017 1.20 (0.99-1.44) 0.06
Each model contains the standard clinical factors used in prior models (age, sex, weight, history of hypertension, history of diabetes mellitus, current tobacco use, prior MI, prior PCI or CABG, systolic blood pressure, estimated GFR, ratio of apoB/apoA, LVEF, aspirin use, beta-blocker use, lipid-lowering medication use) as well as those biomarkers shown with data. HR is for the risk per 1-SD of log-transformed biomarker.
14 Supplemental Table 11 . C-statistics in adjusted multimarker models in the placebo arm Background-Circulating biomarkers can offer insight into subclinical cardiovascular stress and thus have the potential to aid in risk stratification and tailoring of therapy. Methods and Results-We measured plasma levels of 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patients with stable coronary artery disease and preserved left ventricular ejection fraction who were randomized to trandolapril or placebo as part of the Prevention of Events With Angiotensin Converting Enzyme (PEACE) trial. After adjustment for clinical cardiovascular risk predictors and left ventricular ejection fraction, elevated levels of MR-proANP, MR-proADM, and CT-proET-1 were independently associated with the risk of cardiovascular death or heart failure (hazard ratios per 1-SD increase in log-transformed biomarker levels of 1.97, 1.48, and 1.47, respectively; P�0.002 for each biomarker). These 3 biomarkers also significantly improved metrics of discrimination when added to a clinical model. Trandolapril significantly reduced the risk of cardiovascular death or heart failure in patients who had elevated levels of �2 biomarkers (hazard ratio, 0.53; 95% confidence interval, 0.36 -0.80), whereas there was no benefit in patients with elevated levels of 0 or 1 biomarker (hazard ratio, 1.09; 95% confidence interval, 0.74 -1.59; P interaction �0.012). Conclusions-In patients with stable coronary artery disease and preserved left ventricular ejection fraction, our results suggest that elevated levels of novel biomarkers of cardiovascular stress may help identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy. Key Words: angiotensin-converting enzyme inhibitors � biomarkers � coronary disease E levated levels of circulating biomarkers related to cardiac volume or pressure overload offer insight into subclinical cardiac stress and thus have the potential to aid in risk stratification. 1 Specifically, elevated levels of B-type natriuretic peptide (BNP; either the hormone or the aminoterminal fragment of the prohormone [NT-proBNP]) have been shown to be predictive of mortality and/or heart failure events across a broad range of individuals, ranging from the general population to patients with overt heart failure. [1] [2] [3] [4] [5] [6] [7] Clinical Perspective on p Development of newer assays that target more stable epitopes of hormones or prohormones that are released in relation to cardiomyocyte and/or vascular stress offers the potential for more refined risk assessment. Specifically, atrial natriuretic peptide (ANP) is a vasodilator and natriuretic that is synthesized in the myocardium in response to increased wall tension. 8 Adrenomedullin (ADM) is a potent vasodilator synthesized in the adrenal medulla, vascular endothelial cells, heart, and elsewhere in response to physical stretch and specific cytokines, with levels in the heart elevated in the setting of pressure and volume overload. 9,10 Endothelin-1 (ET-1) is a potent vasoconstrictor and profibrotic hormone that is secreted by vascular endothelial cells, with levels correlating with shear stress and pulmonary artery pressure. 11 Copeptin is a stable peptide derived from the precursor to arginine vasopressin, a vasoconstrictor that is secreted from the posterior pituitary in response not only to osmotic stimuli but also to hemodynamic changes detected by cardiac and vascular baroreceptors. 12 Higher levels of these biomarkers have been associated with an increased risk of death and/or heart failure events in patients with established heart failure. [13] [14] [15] [16] The availability of an assay panel for these 4 biomarkers of cardiovascular stress that have shown promise in patients with established heart failure created the opportunity to investigate their utility in a broader population.
Methods
Patient Population
Biomarker Analyses
Outcomes
Statistical Analyses
Baseline characteristics are reported as mean�SD for normally distributed continuous variables and as counts and percentages for categorical variables. Wilcoxon rank-sum and � 2 tests for trend were used to test for differences in continuous and categorical baseline characteristics between quartiles of biomarkers. The Spearman correlation was used to calculate the association between different biomarkers and categorized based on standard cut points. 27 The cumulative incidences of clinical outcomes across quartiles of each biomarker were compared by use of a log-rank test. Cox proportional-hazards models were used to examine the association between biomarker levels and outcome data. In these models, biomarker levels were examined both as a continuous variable (after natural logarithmic transformation) and as a categorical variable by quartiles. Associations were adjusted for age, sex, weight, history of hypertension, history of diabetes mellitus, current tobacco use, prior MI, prior percutaneous coronary intervention or coronary artery bypass grafting, systolic blood pressure, estimated glomerular filtration rate, ratio of apolipoprotein B to apolipoprotein A, LVEF, aspirin use, �-blocker use, and lipid-lowering medication use. Starting with a model containing the aforementioned clinical covariates, a forward selection algorithm (P�0.05 to enter the model) was used to select among the 4 novel biomarkers, as well as NT-proBNP and cTnT. The incremental performance of the biomarkers in addition to clinical predictors was further evaluated by calculating changes in the C statistic, integrated discrimination improvement, and category-free net reclassification improvement metrics (see the Methods section in the online-only Data Supplement for further details). 28 -30 To examine for heterogeneity in the effect of trandolapril on the risk of cardiovascular death or heart failure, hazard ratios (HRs) were calculated in patients who were and were not in the highest-risk category as defined by being in the top quartile of a biomarker level. To test for statistically significant effect modification, a Cox proportional hazards model was created that included a term for trandolapril, a term for biomarker risk category, and an interaction term.
A value of P�0.05 was considered to indicate statistical significance, and all tests were 2 sided. No adjustment for multiple comparisons was performed. Although based on previous work with these biomarkers in other populations, all of the analyses we have performed in this biomarker substudy are inherently exploratory. Analyses were performed with STATA/IC (version 10.1, STATA Corp, College Station, TX) and R (version 2.12.1).
Results
Baseline Characteristics of the Patients and Biomarker Levels
Baseline measurements of the 4 novel biomarkers were available for 3717 patients from the PEACE trial. The clinical characteristics of the patients are given in Table 1 . By design, all patients had stable CAD, and LVEF was preserved at a mean�SD value of 58.7�9.6%. Median levels of MR-proANP, MR-proADM, CT-proET-1, and copeptin at baseline in patients in the PEACE trial were 90.45 pmol/L (25th-75th percentile, 63.68 -128.3 pmol/L), 0.53 nmol/L (25th-75th percentile, 0.45-0.64 nmol/L), 47.82 pmol/L (25th-75th percentile, 39.04 -57.02 pmol/L), and 6.47 pmol/L (25th-75th percentile, 0 -10.67 pmol/L), respectively. The levels tended to be higher than those seen in healthy populations, but with the exception of MR-proADM, the majority of values were lower than the 97.5th percentile reported in healthy populations and lower than the values in patients with overt heart failure (Table II in the online-only Data Supplement). Characteristics of patients according to quartiles of biomarker levels are shown in Tables III through VI in the online-only Data Supplement. In general, higher levels of biomarkers of cardiovascular stress were positively associated with greater age and prevalence of hypertension and lower estimated glomerular filtration rate. LVEF was inversely associated with MR-proANP and copeptin levels but differed by only 2.0 and 1.0 absolute percentage points between the top and bottom quartiles for the 2 biomarkers, respectively. Among the novel biomarkers, the only moderately strong correlation was between MR-proADM and CT-proET-1 (r�0.63); the others were moderate to low (r�0.44; Table VII in the online-only Data Supplement). As expected, there was a strong positive correlation between levels of MR-proANP and NT-proBNP (r�0.76), but correlations of NT-proBNP and cTnT with other markers were weak (r�0.38; Table VII in the online-only Data Supplement).
Clinical Outcomes
Among patients allocated to the placebo arm of the PEACE trial, higher baseline levels of each of the 4 novel biomarker of cardiovascular stress were strongly associated with the subsequent risk of cardiovascular death or heart failure (the composite of which occurred in 114 patients), with up to approximately a doubling of the risk per each 1-SD increase in log-transformed biomarker levels (P�0.002 for each biomarker; Table 2 ). Risk increased across quartiles, especially the fourth quartile ( Figure  1 ). Similar associations were seen between biomarker levels and the risk of cardiovascular death (which occurred in 67 patients) and of heart failure individually (which occurred in 56 patients; Table VIII in the online-only Data Supplement).
After adjustment for traditional clinical risk predictors, estimated glomerular filtration rate, and LVEF (see Methods for a detailed list of covariates), elevated levels of MR-proANP, MR-proADM, and CT-proET-1 remained significantly associated with an increased risk of cardiovascular death or heart failure, ranging from 47% higher risk to a near doubling of the risk per each 1-SD increase in log-transformed biomarker levels (P�0.002 for each biomarker); in terms of quartile analysis, the risk was most pronounced for those patients in the top quartile, who had almost 3 times to �5 times the risk seen for patients in the lowest quartile. In contrast, after multivariable adjustment, the association with copeptin was no longer significant ( Table  3) . As was the case for the unadjusted analyses, similar associations were seen between biomarker levels and the risk of cardiovascular death and of heart failure individually (Table VIII in the online-only Data Supplement). Compared with cardiovascular death, the associations with the less cardiovascular-specific end point of all-cause death were significant but weaker (Table IX in the online-only Data Supplement). As expected on the basis of prior work, 6, 26 there were nonsignificant adjusted associations between levels of novel biomarkers of cardiovascular stress and the risk of acute MI, stroke, or coronary revascularization, with the exception of MR-proANP and stroke (P�0.043; Table IX in the onlineonly Data Supplement). CV indicates cardiovascular; HR, hazard ratio; CI, confidence interval; MR-proANP, midregional pro-atrial natriuretic peptide; MR-proADM, midregional pro-adrenomedullin; and CT-proET-1, C-terminal pro-endothelin-1. A total of 114 of the 1868 patients allocated to placebo experienced CV death or heart failure. Each biomarker was analyzed separately. In quartile analyses, "multiple partial" refers to a 3-df test for the addition of all quartiles and "trend" refers to a 1-df test for linear trend across quartiles.
Sabatine et al Biomarkers of Cardiovascular Stress in Stable CAD
We have previously measured NT-proBNP and cTnT in this population, and the association of those biomarkers with cardiovascular death or heart failure in a model adjusted for the aforementioned clinical covariates is shown in Table X The addition of MR-proANP, MR-proADM, and CTproET-1 individually to the clinical model significantly improved metrics of discrimination (Table 4 ). In contrast, the addition of copeptin did not improve these metrics. The addition CV indicates cardiovascular; HR, hazard ratio; CI, confidence interval; MR-proANP, midregional pro-atrial natriuretic peptide; MR-proADM, midregional pro-adrenomedullin; and CT-proET-1, C-terminal pro-endothelin-1. Covariates in the model include standard clinical factors: age, sex, weight, history of hypertension, history of diabetes mellitus, current tobacco use, prior myocardial infarction, prior percutaneous coronary intervention or coronary artery bypass graft surgery, systolic blood pressure, estimated glomerular filtration rate, ratio of apolipoprotein B to A, left ventricular ejection fraction, aspirin use, �-blocker use, and lipid-lowering medication use. Each biomarker was analyzed separately in the placebo arm. In quartile analyses, "multiple partial" refers to a 3-df test for the addition of all quartiles and "trend" refers to a 1-df test for linear trend across quartiles.
of all 3 biomarkers to the clinical model improved the C statistic from 0.768 to 0.809 and yielded an integrated discrimination improvement of 4.6% and an net reclassification improvement of 0.435 (all P�0.0005). Adding MR-proANP, MR-proADM, and CT-proET-1 uniformly and significantly improved the C statistic of multivariable models already containing clinical covariates, regardless of whether NT-proBNP, cTnT, or both were also in the model; conversely, adding NT-proBNP and cTnT to a model containing clinical covariates as well as MR-proANP, MR-proADM, and CT-proET-1 did not improve the C statistic (Table XI in the online-only Data Supplement).
Interaction With Trandolapril Therapy
A gradient of benefit (P interaction �0.016) with trandolapril therapy was observed in patients categorized according to whether they had elevated levels of 0 (n�2037), 1 (n�891), 2 (n�472), or all 3 (n�317) novel biomarkers that we found to be associated with cardiovascular death or heart failure in adjusted analyses ( Figure 2B ). When the results were dichotomized, among the 2928 patients (79% of the biomarker cohort) with �1 elevated biomarker, there was no benefit of trandolapril therapy on the risk of cardiovascular death or heart failure (HR, 1.09; 95% CI, 0.74 -1.59), whereas among the 789 patients (21% of the biomarker cohort) with �2 elevated biomarkers, trandolapril significantly reduced the rate of cardiovascular death or heart failure (HR, 0.53; 95% CI, 0.36 -0.80; P�0.002, P interaction �0.012; Figure 3 ). The absolute risk reduction over 6 years in this latter group was 7.5%; thus, in this subset, 14 patients would need to be treated with trandolapril for 6 years to prevent a cardiovascular death or hospitalization for heart failure.
Discussion
In an exploratory analysis among a large cohort of patients with stable CAD and preserved LVEF, we have demonstrated that elevated levels of 3 novel biomarkers of cardiovascular stress are independently associated with the subsequent risk of cardiovascular death and heart failure. Specifically, MRproANP, MR-proADM, and CT-proET-1 were associated with cardiovascular death or heart failure independently of clinical factors, renal function, and LVEF, ranging from 47% higher risk to a near doubling of the risk per each 1-SD increase in log-transformed biomarker levels and almost 3 times to �5 times the risk for patients in the highest compared with the lowest quartile. In contrast, a fourth biomarker, copeptin, was not independently associated with the risk of cardiovascular events. Moreover, and in contrast to previous results with other biomarkers, including NTproBNP and cTnT, 6, 26, 31 elevated levels of these 3 biomarkers identified patients in whom, despite appearing to be at low risk clinically, therapy with an ACE inhibitor resulted in a significant reduction in the risk of cardiovascular death or heart failure.
Critically, whereas other biomarker analyses have been embedded in observational cohorts, we had the benefit of studying these biomarkers in a randomized clinical trial, allowing us to examine the interaction between baseline biomarker levels and the efficacy of the randomized therapy without concern for the inherent bias in examining nonrandomly allocated therapies. Using a panel of these novel biomarkers of cardiovascular stress, we were able to identify approximately one fifth of enrolled patients with stable CAD in whom ACE inhibitor therapy nearly halved the risk of cardiovascular death or heart failure. Our findings are conceptually analogous to the results of Richards and colleagues, 33, 34 who showed that elevated levels of biomarkers of cardiovascular stress identified patients with ischemic left ventricular dysfunction who benefited from �-blockade.
Current practice guidelines for the management of patients with stable CAD recommend ACE inhibitor therapy in those patients with an LVEF �40%; in addition, in part on the basis of data from the Heart Outcomes Prevention Evaluation (HOPE) trial, ACE inhibitors are recommended for patients who are relatively high risk and/or have another compelling clinical indication (eg, hypertension, diabetes mellitus, or chronic kidney disease). 35 In contrast, for lower-risk patients like those in the PEACE trial, in which the event rate in the placebo arm was lower than the event rate in the ACE inhibitor arm from the HOPE trial, the guidelines note that it is reasonable but not recommended to use ACE inhibitors when cardiovascular risk factors are well controlled and revascularization has been performed. Our data now support the hypothesis that within this very large population of patients who appear to be of lower risk clinically, biomarkers of cardiovascular stress levels may be useful to help guide such decision making. Although additional prospective analyses will need to be done if these biomarkers become available for routine clinical use in the United States, targeting long-term drug therapy based on a panel of biomarkers should be cost effective.
Several potential limitations of our study deserve consideration. The PEACE clinical trial population, which was predominantly a white, male population �50 years of age, is not representative of the general population. However, the clinical and laboratory characteristics of patients in this study are typical of patients with stable coronary disease, and a high proportion of patients were treated with �-blockers and lipid-lowering therapy. Blood samples were obtained from only a subgroup of the participants in the overall PEACE trial, but there were no clinically relevant differences between patients who did and did not participate in the biomarker substudy. Banked biosamples were used, but any sample degradation should be random with respect to cardiovascular outcomes, and thus any resultant misclassification should only bias toward the null hypothesis. The formation of the multimarker score for interaction with therapy should be considered exploratory, and the optimal combination of biomarkers and their cut points merits validation in additional populations. Heart failure events were not a component of the prespecified primary outcome in the original trial design but are a well-established outcome predicted by biomarkers of cardiac stress and prevented by ACE inhibitors in other populations. 6, 19, 20, 26 
Conclusion
In apparently low-risk patients with stable CAD and preserved LVEF, elevated levels of novel biomarkers reflecting cardiovascular stress may be useful both to identify patients who are at higher risk of cardiovascular death and heart failure and to select patients who derive a significant benefit from ACE inhibitor therapy. Mots clés : inhibiteurs de l'enzyme de conversion de l'angiotensine biomarqueurs maladie coronaire L 'élévation des taux de biomarqueurs circulants découlant de l'augmentation de la précharge ou de la postcharge cardiaque témoigne de l'existence d'un stress cardiovasculaire infraclinique et pourrait, dès lors, constituer un élément susceptible de faciliter la stratification des risques. 1 De fait, il a été démontré que l'augmentation du taux de peptide natriurétique de type B (BNP ; l'observation valant pour l'hormone elle-même et pour le fragment amino-terminal de son précurseur [NT-proBNP]) est prédictive de décès et/ou d'insuffisance cardiaque chez de multiples catégories d'individus, depuis la population générale jusqu'aux patients atteints d'insuffisance cardiaque avérée. [1] [2] [3] [4] [5] [6] [7] Le développement de méthodes de dosage innovantes ayant pour cibles les épitopes plus stables des hormones et prohormones qui sont libérées en réponse aux agressions dont sont l'objet les cardiomyocytes et/ou l'appareil vasculaire est de nature à permettre une évaluation plus fine des risques. Plus précisément, le peptide natriurétique atrial (ANP) est une substance vasodilatatrice et natriurétique qui est synthétisée par le myocarde lorsque la tension pariétale augmente. 9,10 L'endothéline de type 1 (ET-1) est à la fois un puissant vasoconstricteur et une hormone profibrotique qui est sécrétée par les cellules de l'endothélium vasculaire et dont le taux augmente parallèle-ment aux forces de cisaillement et à la pression artérielle pulmonaire.
11 La copeptine est un peptide stable issu du précurseur de l'arginine-vasopressine, un vasoconstricteur sécrété par la post-hypophyse en réponse à la fois aux stimuli osmotiques et aux modifications hémodynamiques détectées par les barorécepteurs cardiaques et vasculaires. 12 Il a été établi que, chez les patients atteints d'insuffisance cardiaque avérée, l'élévation des taux de ces marqueurs biologiques est corrélée avec l'augmentation du risque de décès et/ou d'événement lié à l'insuffisance cardiaque. [13] [14] [15] [16] Le fait que le dosage de ces quatre biomarqueurs du stress cardiovasculaire soit désormais réalisable par des méthodes d'analyse dont l'apport potentiel a été démontré chez les patients en question a tout naturellement conduit à examiner leur utilité dans une population plus vaste.
Les inhibiteurs de l'enzyme de conversion de l'angiotensine (IEC) réduisent significativement le risque de décès et d'événements liés à l'insuffisance cardiaque chez les patients atteints d'une telle affection, leur impact bénéfique étant maximal dans les formes cliniques les plus sévères. 17 Chez les patients présentant un infarctus du myocarde (IDM) en phase aiguë, les IEC exercent leur effet bénéfique le plus marqué lorsque l'IDM présente des caractéristiques cliniques à haut risque telles qu'une localisation à la paroi antérieure ou une altération de la fonction systolique ventriculaire gauche. 18 En revanche, les données sont moins tranchées en ce qui concerne le rôle joué par ces médicaments chez les patients coronariens stables exposés à un risque plus faible car indemnes d'insuffisance cardiaque. [19] [20] [21] Les hypothèses que nous avons donc cherché à vérifier étaient, d'une part, que, chez ces patients, l'élévation des taux de fragments médians du pro-ANP (MR-proANP), de la proADM, de fragment C-terminal de la proET-1 (CT-proET -1) 
Méthodes Population de l'étude
L'étude a porté sur 3 717 patients atteints d'une maladie coronaire stable documentée qui avaient été inclus dans l'essai PEACE (www.ClinicalTrials.gov ; identifiant unique : NCT00000558) et chez lesquels un échantillon sanguin avait été prélevé à leur entrée dans l'essai. Le plan d'organisation et les principaux résultats de PEACE ont été précédemment publiés, 21 les aspects majeurs étant détaillées au chapitre « Méthodes » et dans le Tableau I du supplément de données uniquement disponible en ligne. En résumé, les patients n'étaient pas insuffisants cardiaques à leur entrée dans l'étude et aucun n'avait été hospitalisé pour un syndrome coronaire aigu ni n'avait fait l'objet d'une intervention de revascularisation coronaire dans les 3 mois ayant précédé son inclusion. L'étude mère et la présente sous-étude ont toutes deux été approuvées par les comités d'éthique des établissements concernés et tous les patients ont fourni leur consentement éclairé.
Analyse des marqueurs biologiques
Les taux plasmatiques initiaux de MR-proANP, 22 MR-proADM, 23 CT-proET-1 24 et copeptine (coffrets de dosage B.R.A.H.M.S. Gmbh, Henningsdorf, Allemagne) ont été mesurés dans le laboratoire des essais cliniques TIMI (Thrombolysis in Myocardial Infarction [thrombolyse dans l'infarctus du myocarde]) (Boston, Massachusetts, Etats-Unis) comme décrit au chapitre « Méthodes » et dans le Tableau II du supplément de données uniquement disponible en ligne. Les taux de NT-proBNP et de troponine T cardiaque (TnTc) avaient également été mesurés chez ces patients à l'entrée dans l'essai par une méthode de dosage hautement sensible, comme cela a été précédemment publié et est résumé au chapitre « Méthodes » du supplément de données uniquement disponible en ligne. 6, 26 Les dosages ont tous été réalisés par du personnel qui ignorait les résultats cliniques et le traitement assigné aux patients.
Critères de jugement
En nous fondant sur les données ayant établi la valeur prédictive des biomarqueurs du stress cardiovasculaire, 6 nous avons retenu comme critère de jugement principal de l'étude l'incidence de l'événement composite regroupant le décès de cause cardiovasculaire et l'hospitalisation pour insuffisance cardiaque. Nous avons également examiné d'autres événements cardiovasculaires majeurs qui avaient été pris en compte chez les patients de l'étude, à savoir le décès lié à toute cause, l'IDM aigu, l'accident vasculaire cérébral en phase aiguë et les procédures de revascularisation coronaire (par approche percutanée ou chirurgicale). Les modalités de validation des événements sont détaillées au chapitre « Méthodes » du supplément de données uniquement disponible en ligne. Tous les événements cliniques ont été qualifiés préalablement au dosage des marqueurs biologiques. 27 Un test des rangs logarithmiques a été effectué pour comparer les incidences cumulées d'événements cliniques entre les quartiles de taux de chaque marqueur biologique. Des modèles à risques proportionnels de Cox ont été utilisés pour analyser les relations entre les taux de biomarqueurs et les événements cliniques. Dans les modèles en question, les taux de biomarqueurs ont été examinés à la fois en tant que variables continues (après transformation en leur logarithme naturel) et en tant que variables catégorielles classées par quartile. Les liens observés ont été ajustés pour l'âge, le sexe, le poids corporel, l'hypertension artérielle, le diabète, l'existence d'un tabagisme, les antécédents d'IDM et d'intervention coronaire percutanée ou de pontage aorto-coronaire, la pression artérielle systolique, le taux de filtration glomérulaire estimé, le rapport apolipoprotéine B/apolipoprotéine A, la FEVG et les prescriptions d'aspirine, de bêtabloquants et d'hypolipémiants. En commençant par un modèle qui regroupait toutes les covariables cliniques mentionnées ci-dessus, nous avons employé un algorithme de sélection par éliminations successives (dans lequel le degré de significativité des variables devait atteindre une valeur de p inférieure à 0,05 pour que celles-ci puissent être conservées dans le modèle) pour départager les quatre biomarqueurs nouvellement validés, auxquels ont été ajoutés le NT-proBNP et la TnTc. L'augmentation du pouvoir prédictif conféré par l'inclusion de ces biomarqueurs, par rapport à la valeur informative des facteurs cliniques, a été également évaluée en examinant les modifications qui en avaient résulté en termes de statistique C, d'amélioration de la discrimination intégrée et d'amélioration de la reclassification nette indépendante de la catégorie (pour de plus amples détails, se reporter au chapitre « Méthodes » du supplément de données uniquement disponible en ligne). [28] [29] [30] Pour juger de l'hétérogénéité de l'effet du trandolapril sur le risque de décès de cause cardiovasculaire ou d'insuffisance cardiaque, les risques relatifs (RR) ont été calculés selon que les patients se situaient ou non dans la catégorie de risque la plus élevée, c'est-à-dire dans le plus haut quartile de taux de l'un des biomarqueurs considérés. Pour rechercher une éventuelle modification statistiquement significative de l'effet exercé, nous avons conçu un modèle à risques proportionnels de Cox qui prenait en compte l'administration de trandolapril, la catégorie de risque définie par le taux de biomarqueur et l'interaction entre les deux.
Analyses statistiques
Les valeurs de p inférieures à 0,05 ont été considérées comme statistiquement significatives, les tests effectués ayant tous été bidirectionnels. Aucun ajustement n'a été pratiqué pour les comparaisons multiples. Bien qu'elles aient été fondées sur de précédents travaux menés sur ces marqueurs biologiques dans d'autres populations, toutes les analyses que nous avons effectuées dans cette sous-étude avaient par essence un caractère exploratoire. Les analyses ont été réalisées au moyen des programmes STATA/IC version 10.1 (STATA Corp., College Station, Texas, Etats-Unis) et R version 2.12.1.
Résultats Caractéristiques des patients et taux de biomarqueurs à l'entrée dans l'étude
Les valeurs des quatre biomarqueurs biologiques avaient été mesurées chez 3 717 patients de l'essai PEACE à leur entrée dans ce dernier. Les caractéristiques cliniques des patients sont résumées dans le Tableau 1. Aux termes du protocole, les patients étaient tous des coronariens stables dont la FEVG était conservée à une valeur moyenne (± ET) de 58,7 ± 9,6 %. Les taux tendaient à être supérieurs à ceux observés chez le sujet sain, mais, exception faite du taux de MR-proADM, la majorité des valeurs se situait en dessous du 97,5 ème percentile rapporté dans les populations en bonne santé et en dessous des taux mesurés chez les patients atteints d'insuffisance cardiaque avérée (Tableau II du supplément de données uniquement disponible en ligne). Les caractéristiques des patients en fonction des quartiles de taux des marqueurs biologiques sont présentées dans les Tableaux III à VI du supplément de données uniquement disponible en ligne. De façon générale, l'élévation des taux de biomarqueurs du stress cardiovasculaire a été proportionnelle à l'âge, à la prévalence de l'hypertension artérielle et à l'altération du taux de filtration glomérulaire estimé. La FEVG s'est révélée inversement proportionnelle aux taux de MR-proANP et de copeptine, mais les différences absolues relevées entre les quartiles supérieur et inférieur de chacun de ces deux biomarqueurs n'ont été que de, respectivement, 2,0 et 1,0 %. Parmi les quatre marqueurs, seuls le MR-proADM et le CT-proET-1 ont présenté une corrélation relativement forte (r = 0,63) ; pour les deux autres, les corrélations ont été modérées à faibles (r ≤0,44 ; Tableau VII du supplément de données uniquement disponible en ligne). 
Evénements cibles cliniques
Chez les patients de l'essai PEACE qui avaient reçu le placebo, les taux initiaux de chacun des quatre biomarqueurs du stress cardiovasculaire se sont montrés étroitement corrélés avec le risque de décès de cause cardiovasculaire ou d'insuffisance cardiaque (l'événement composite étant survenu chez 114 patients), chaque élévation de 1 ET du logarithme naturel des taux de marqueurs s'étant traduite par un quasi-doublement du risque (p ≤0,002 pour chaque marqueur biologique ; Tableau 2). Le risque a augmenté avec les quartiles, son niveau étant apparu particulièrement élevé pour le quatrième d'entre eux ( Figure 1 ). Des liens similaires ont été relevés entre les taux de marqueurs biologiques et les risques spécifiques de décès de cause cardiovasculaire (survenu chez 67 patients) et d'insuffisance cardiaque (observée chez 56 patients ; Tableau VIII du supplément de données uniquement disponible en ligne).
Après ajustement pour les facteurs de risque classiques, le taux de filtration glomérulaire attendu et la FEVG (se reporter à la rubrique « Méthodes » pour une description détaillée des covariables), l'élévation des taux de MRproANP, MR-proADM et CT-proET-1 est demeurée significativement corrélée avec l'augmentation du risque de décès de cause cardiovasculaire ou d'insuffisance cardiaque, chaque élévation de 1 ET du logarithme naturel des taux de ces marqueurs ayant entraîné des augmentations du risque allant de 47 % à un taux près de deux fois supérieur (p ≤0,002 pour chaque marqueur biologique) ; dans l'analyse par quartile, le risque maximal a été observé chez les patients dont les taux se situaient dans le quartile le plus élevé ; les niveaux de risque ont, en effet, excédé de près du triple à plus de 5 fois ceux constatés chez les patients classés dans le quartile le plus faible. Toutefois, après ajustement multivarié, le lien relevé avec le taux de copeptine a perdu sa significativité (Tableau 3 
Interaction avec le traitement par le trandolapril
Dans la cohorte totale, tous biomarqueurs confondus, l'administration de trandolapril a été associée à un RR de décès de cause cardiovasculaire ou d'insuffisance cardiaque chiffré à 0,80 (IC à 95 % : 0,61 à 1,05). Il importe toutefois de noter que, chez les patients dont le taux de MR-proANP, de MR-proADM ou de CT-proET-1 se situait dans le quartile le plus élevé et qui, de ce fait, étaient exposés au risque maximal de décès de cause cardiovasculaire ou d'insuffisance cardiaque sur la base de ces marqueurs biologiques, le trandolapril a entraîné une diminution significative de ce risque, comprise entre 34 et 44 %, alors qu'il n'a eu aucun effet bénéfique chez les patients qui encouraient des risques plus faibles (Figure 2A ). En revanche, la prescription de trandolapril n'a entraîné aucune amélioration significative chez les patients dont le taux de NT-proBNP ou de TnTc se situait dans le quartile les plus élevé (Figure I du supplément de données uniquement disponible en ligne). Nous avons constaté un gradient de bénéfice exercé par le trandolapril (p interaction = 0,016) chez les patients selon qu'ils ne présentaient aucune élévation des nouveaux biomarqueurs dont les analyses ajustées avaient montré qu'ils étaient corrélés avec le risque de décès de cause cardiovasculaire ou d'insuffisance cardiaque (n = 2 037), qu'un seul de ces marqueurs était augmenté (n = 891), que deux marqueurs étaient augmentés (n = 472) ou que les trois étaient augmentés (n = 317) ( Figure 2B ). En dissociant les résultats, nous avons observé que, chez les 2 928 patients dont au plus un seul biomarqueur était augmenté (soit 79 % de la cohorte dans laquelle les biomarqueurs avaient été mesurés), l'administration de trandolapril n'avait pas eu d'impact bénéfique sur le risque de décès de cause cardiovasculaire ou d'insuffisance cardiaque (RR : 1,09 ; IC à 95 % : 0,74 à 1,59), alors que, chez les 789 sujets qui présentaient des élévations d'au moins deux biomarqueurs (21 % de la cohorte), elle a significativement diminué l'incidence de l'événement composite (RR : 0,53 ; IC à 95 % : 0,36 à 0,80 ; p = 0,002, p interaction = 0,012 ; Figure 3 ). Dans ce dernier sous-groupe, la diminution du risque absolu sur 6 ans a atteint 7,5 %, ce qui signifie qu'il convient de traiter 14 patients du sous-groupe en question pendant 6 ans pour prévenir un décès de cause cardiovasculaire ou une hospitalisation pour insuffisance cardiaque.
Discussion
Dans une analyse exploratoire effectuée sur une vaste cohorte de patients coronariens stables dont la FEVG était conservée, nous avons démontré que les élévations des taux de trois marqueurs biologiques du stress cardiovasculaire nouvellement décrits constituent des facteurs indépendants d'augmentation du risque de décès de cause cardiovasculaire ou d'insuffisance cardiaque. De fait, un lien a pu être établi entre les taux de MR-proANP, MR-proADM et CT-proET-1 et le décès d'origine cardiovasculaire ou l'insuffisance cardiaque indépendamment des facteurs cliniques, de la fonction rénale et de la FEVG ; chaque élévation de 1 ET du logarithme naturel du taux de ces marqueurs s'est, en effet, traduite par une augmentation du risque variant de 47 % à près du double et, chez les patients dont les taux se situaient dans le quartile le plus élevé, le risque a augmenté à un niveau compris entre près du triple et plus du quintuple comparativement à celui observé chez les individus classés dans le quartile le plus faible. En revanche, un quatrième biomarqueur, la copeptine, n'a présenté aucun lien propre avec le risque d'événement cardiovasculaire. Surtout, et contrairement à ce qui avait été précédemment rapporté pour d'autres marqueurs, dont le NT-proBNP et la TnTc, 6, 26, 31 l'existence d'une élévation d'un ou plusieurs des trois biomarqueurs mentionnés a constitué un élément de caractérisation des patients chez lesquels l'administration d'un IEC a significativement réduit le risque de décès de cause cardiovasculaire ou d'insuffisance cardiaque, alors même que, sur la base des critères cliniques, ils paraissaient n'encourir qu'un faible risque.
Nous n'avons pas directement mesuré les taux d'ANP, d'ADM et d'ET-1, mais ceux de leurs prohormones, car celles-ci sont libérées en proportion équimolaire par rapport aux hormones vasoactives mais ont une demi-vie plus longue. Par ailleurs, lorsque cela était possible, nous avons préféré doser le taux de fragment médian, car ce dernier est plus stable in vivo et ex vivo que les portions amino-et carboxyterminales de la prohormone, ce qui minimise le risque de sous-estimation des taux lié à la dégradation précoce des épitopes majeurs situés aux deux extrémités de la molécule. Dans des études menées chez des patients atteints d'insuffisance cardiaque documentée, l'élévation des taux dele MR-proADM avaient été ceux pour lesquels les corrélations avaient été les plus puissantes, celles-ci s'étant révélées supérieures à celles observées pour le NT-proBNP et pour la TnTc mesurée par une méthode hautement sensible. Dans la mesure où notre étude avait un fondement clinique plutôt que mécaniste, nous ne pouvons que spéculer sur les raisons de cette supériorité, qui peut notamment tenir à de discrètes différences dans les voies physiopathologiques qui sous-tendent l'élévation des taux de chacun de ces biomarqueurs ou aux propriétés analytiques plus favorables et qui, donc, permettent mieux de dépister les troubles cardiovasculaires infracliniques. Cela étant, nos données corroborent et prolongent par plusieurs aspects les observations rapportées par Schnabel et al 7 sur ces marqueurs biologiques et leurs relations avec l'athérosclérose ; elles portent, en effet, sur des patients qui n'étaient pas insuffisants cardiaques à leur entrée dans l'étude et dont les FEVG étaient connues et ont été incluses dans tous les modèles multivariés ; notre cohorte de patients avait, en outre, pour origine un nombre beaucoup plus élevé de centres cliniques et nous avons spécifiquement axé nos analyses sur les événements cliniques que les biomarqueurs du stress cardiovasculaire sont le mieux à même de prédire, à savoir le décès de cause cardiovasculaire et l'insuffisance cardiaque, plutôt que sur un événement composite incluant le décès ou l'IDM.
Elément fondamental, alors que les précédentes analyses de marqueurs biologiques avaient été incluses dans des études de cohortes observationnelles, nous avons eu la faculté d'étudier les présents marqueurs dans le cadre d'un essai clinique randomisé, ce qui nous a permis d'examiner l'interaction entre leurs taux initiaux et l'efficacité du traitement assigné par la randomisation en nous exonérant du biais inhérent à l'évaluation de traitements alloués de façon non randomisée. En nous appuyant sur plusieurs de ces nouveaux biomarqueurs du stress cardiovasculaire, nous avons pu établir que, chez près du cinquième des patients coronariens stables de l'essai, l'administration d'un IEC avait pratiquement réduit de moitié le risque de décès de cause cardiovasculaire ou d'insuffisance cardiaque. Nos résultats rejoignent conceptuellement les observations de Richards et al, 33, 34 qui avaient montré que la présence de taux augmentés de biomarqueurs du stress cardiovasculaire permet d'identifier les patients présentant une dysfonction ventriculaire gauche d'origine ischémique chez lesquels l'administration d'un bêtabloquant est bénéfique.
Selon les actuelles recommandations en matière de prise en charge des patients coronariens stables, la prescription d'un IEC est conseillée chez ceux dont la FEVG est inférieure à 40 % ; de plus, en partie en raison des données de l'essai HOPE (Heart Outcomes Prevention Evaluation [étude sur la prévention des événements cardiaques]), les IEC sont également recommandés chez les patients exposés à un risque relativement élevé et/ou qui relèvent d'une autre indication clinique majeure (telle que la présence d'une hypertension artérielle, d'un diabète ou d'une néphropathie chronique). 35 En revanche, chez les patients qui encourent un risque moins important, comme cela était le cas de ceux de l'essai PEACE, dans lequel le taux d'événements enregistré dans le groupe placebo a été inférieur à celui observé dans le groupe de l'essai HOPE qui avait reçu l'IEC, les recommandations stipulent qu'il est licite, sans que cela soit expressément requis, de prescrire un IEC dès lors que les facteurs de risque cardiovasculaire sont bien contrôlés et qu'une revascularisation a été pratiquée. Nos présentes données confortent l'hypothèse selon laquelle, dans cette population extrêmement vaste de patients qui, cliniquement, paraissent encourir un risque moindre, le dosage des taux de biomarqueurs du stress cardiovasculaire pourrait être un utile auxiliaire pour décider de l'attitude à adopter. Bien que d'autres études prospectives doivent être entreprises si la mesure de ces marqueurs biologiques venait à entrer dans la pratique clinique courante aux Etats-Unis, l'attitude consistant à asseoir le choix du traitement médicamenteux à long terme sur une série de biomarqueurs serait sans doute intéressante en termes de rapport coût/efficacité.
Notre étude présente plusieurs limites potentielles qu'il convient d'examiner. La cohorte de l'essai clinique PEACE, qui était principalement constituée d'hommes blancs âgés de plus de 50 ans, n'est nullement représentative de la population générale. Pour autant, les caractéristiques cliniques des patients inclus dans notre étude sont celles classiquement observées chez les individus atteints d'une maladie coronaire stable ; de plus, beaucoup de ces patients recevaient des bêtabloquants et des hypolipémiants. Les prélèvements sanguins ont été uniquement effectués dans un sous-groupe de participants à l'essai principal PEACE ; toutefois, il n'existait pas de différence cliniquement significative entre les patients inclus dans notre sous-étude sur les marqueurs biologiques et ceux qui n'y ont pas pris part. Bien que nous ayons utilisé des échantillons biologiques stockés, l'éventuelle dégradation de certains de ces échantillons ne pouvait qu'avoir un caractère aléatoire quant à son influence sur les événements cardiovasculaires, de sorte que les erreurs de classement qui en auraient découlé auraient uniquement biaisé les résultats dans le sens de l'hypothèse nulle. L'élaboration du score fondé sur les différents marqueurs pour évaluer l'interaction avec le traitement doit être considérée comme exploratoire, car la combinaison optimale de biomarqueurs et les valeurs seuils de ces derniers demandent à être validées dans d'autres populations. L'insuffisance cardiaque ne constituait pas un élément du critère de jugement principal prédéfini dans le plan d'organisation de l'essai originel ; elle représente néanmoins un type d'événement dont il a été clairement établi, dans d'autres populations, que sa survenue peut être anticipée par la mesure des taux de biomarqueurs du stress cardiovasculaire et prévenue par l'administration d'un IEC. 6, 19, 20, 26 
Conclusion
Chez les patients apparemment exposés à un faible risque qui présentent une maladie coronaire stable avec conservation de la FEVG, la mise en évidence de taux augmentés des nouveaux biomarqueurs du stress cardiovasculaire peut permettre de dépister ceux d'entre eux qui encourent un risque plus élevé de décès de cause cardiovasculaire ou d'insuffisance cardiaque et, par ailleurs, d'identifier ceux chez lesquels la prescription d'un IEC serait hautement bénéfique.
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